PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
Today, Anza, a leading solar and energy storage development and procurement platform, announced expanded platform capabilities to enable developers, IPPs, EPCs, and utilities to quickly and ...
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...
PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...
Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...
On Wednesday, PTC 19, formerly known as Invest 99L, was over 400 miles east of Isla Guanaja, Honduras, and 290 miles ...
These live maps from the FOX Forecast Center show the latest information and models on Potential Tropical Cyclone Nineteen, ...
The monkeys made a break for it Wednesday after an employee at the Alpha Genesis facility in Yemassee didn't fully lock a ...